Engineered long terminal repeats of retroviral vectors enhance transgene expression in hepatocytes in vitro and in vivo

Molecular Therapy

Volumn 8, Issue 5, 2003, Pages 796-803

  Yamaguchi, Kanji ^a,b   Itoh, Katsuhiko ^a   Ohnishi, Naoki ^a   Itoh, Yoshito ^b   Baum, Christopher ^c   Tsuji, Takashi ^d   Nagao, Toshikazu ^a   Higashitsuji, Hiroaki ^a   Okanoue, Takeshi ^b   Fujita, Jun ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Hepatocyte; Liver; LTR; Retrovirus; SFFV; Vector

Indexed keywords

CIS ACTING ELEMENT; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SP1;

ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA FLANKING REGION; ENHANCER REGION; GENE EXPRESSION; GENE LOCATION; GENETIC ANALYSIS; GENETIC ENGINEERING; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CELL CARCINOMA; LONG TERMINAL REPEAT; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; POLYCYTHEMIA; PROMOTER REGION; PROTEIN BINDING; SPLEEN FOCUS FORMING VIRUS; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN; WILD TYPE;

ANIMALIA; HEPATITIS B VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; MURINE LEUKEMIA VIRUS; ONCOVIRINAE; SPLEEN FOCUS-FORMING VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 10744224597     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.08.005     Document Type: Article

References (36)

1. Mulligan, R. C. (1993). The basic science of gene therapy. Science 260: 926-932.
2. Robbin, P. D., and Ghivizzni, S. C. (1998). Viral vectors for gene therapy. Pharmacol. Ther. 80: 35-47.
3. Kay, M. A., et al. (1993). In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 262: 117-119.
4. Kay, M. A. (1998). Hepatic gene therapy for haemophilia B: Haemophilia 4: 389-392.
5. Golemis, E. A., Speck, N. A., and Hopkins, N. (1990). Alignment of U3 region sequences of mammalian type C viruses: identification of highly conserved motifs and implications for enhancer design. J. Virol. 64: 534-542.
6. Wang, S., et al. (1993). Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol. Cell. Biol. 13: 3324-3339.
7. Nielsen, A. L., Norby, P. L., Pedersen, F. S., and Jorgensen, P. (1996). Various modes of basic helix-loop-helix protein-mediated regulation of murine leukemia virus transcription in lymphoid cell lines. J. Virol. 70: 5893-5901.
8. Barat, C., and Rassart, E. (1998). Members of the GATA family of transcription factors bind to the U3 region of Cas-Br-E and graffi retroviruses and transactivate their expression. J. Virol. 72: 5579-5588.
9. Granger, S. W., and Fan, H. (1998). In vivo footprinting of the enhancer sequences in the upstream long terminal repeat of Moloney murine leukemia virus: differential binding of nuclear factors in different cell types. J. Virol. 72: 8961-8970.
10. Zaiman, A. L., Nieves, A., and Lenz, J. (1998). CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes. J. Virol. 72: 3129-3137.
11. Baum, C., et al. (1997). The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF. J. Virol. 71: 6323-6331.
12. Tsukiyama, T., Ueda, H., Hirose, S., and Niwa, O. (1992). Embryonal long terminal repeat-binding protein is a murine homolog of FTZ-F1, a member of the steroid receptor superfamily. Mol. Cell. Biol. 12: 1286-1291.
13. Flanagan, J. R., Krieg, A. M., Max, E. E., and Khan, A. S. (1989). Negative control region at the 5′ end of murine leukemia virus long terminal repeats. Mol. Cell. Biol. 9: 739-746.
14. Wahlers, A., et al. (2002). Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells. Mol. Ther. 6: 313-320.
15. Ostertag, W., et al. (1987). Transforming genes and target cells of murine spleen focus-forming viruses. Adv. Cancer Res. 48: 193-355.
16. Baum, C., Hegewisch-becker, S., Eckert, H.-G., Stocking, C., and Ostertag, W. (1995). Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J. Virol. 69: 7541-7547.
17. - cells expanded in vitro: cis elements of FMEV are superior to those of Mo-MuLV. Hum. Gene Ther. 11: 271-284.
18. Danno, S., et al. (1999). Efficient gene transfer by hybrid retroviral vectors to murine spermatogenic cells. Hum. Gene Ther. 10: 1819-1831.
19. Ohnishi, N., et al. (2002). High expression of transgenes mediated by hybrid retroviral vectors in hepatocytes: comparison of promoters from murine retroviruses in vitro and in vivo. Gene Ther. 9: 303-306.
20. Knowles, B. B., Howe, C. C., and Aden, D. P. (1980). Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209: 497-499.
21. Chen, L., Glover, J. N., Hogan, P. G., Rao, A., and Harrison, S. C. (1998). Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA. Nature 392: 42-48.
22. Miyakawa, H., Woo, S. K., Dahl, S. C., Handler, J. S., and Kwon, H. M. (1999). Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc. Natl. Acad. Sci. USA 96: 2538-2542.
23. Jauliac, S., et al. (2002). The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat. Cell Biol. 4: 540-544.
24. Lopez-Rodriguez, C., Aramburu, J., Rakeman, A. S., and Rao, A. (1999). NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc. Natl. Acad. Sci. USA 96: 7214-7219.
25. Black, A. R., Black, J. D., and Azizkhan-Clifford, J. (2001). Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J. Cell. Physiol. 188: 143-160.
26. Wang, Y., et al. (1990). A new enhancer element, ENII, identified in the X gene of hepatitis B virus. J. Virol. 64: 3977-3981.
27. Su, H., and Yee, J. K. (1992). Regulation of hepatitis B virus gene expression by its two enhancers. Proc. Natl. Acad. Sci. USA 89: 2708-2712.
28. Wu, X., Holschen, J., Kennedy, S. C., and Ponder, K. P. (1996). Retroviral vector sequences may interact with some internal promoters and influence expression. Hum. Gene Ther. 7: 159-171.
29. Hafenrichter, D. G., Wu, X., Rettinger, S. D., Kennedy, S. C., Flye, M. W., and Ponder, K. P. (1994). Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood 84: 3394-3404.
30. Okuyama, T., et al. (1996). Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo. Hum. Gene Ther. 7: 637-645.
31. Snyder, R. O., et al. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16: 270-276.
32. Park, F., Ohashi, K., Chiu, W., Naldini, L., and Kay, M. A. (2000). Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat. Genet. 24: 49-52.
33. Doi, I., Mamba, M., and Sato, I. (1975). Establishment and some characteristics of human hepatoma cell lines. Jpn. J. Cancer Res. 66: 385-392.
34. Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T., and Sato, J. (1982). Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42: 3858-3863.
35. Kitamura, T., Onishi, M., Kinoshita, S., Shibuya, A., Miyajima, A., and Nolan, G. P. (1995). Efficient screening of retroviral cDNA expression libraries. Proc. Natl. Acad. Sci. USA 92: 9146-9150.
36. Yang, J., Friedman, M. S., Bian, H., Crofford, L. J., Roessler, B., and McDonagh, K. T. (2002). Highly efficient genetic transduction of primary human synoviocytes with concentrated retroviral supernatant. Arthritis Res. 4: 215-219.